I-Mab
Suite 802, West Tower, OmniVision
88 Shangke Road
Pudong District
Shanghai
201210
China
Tel: 86-21-6057 8000
Website: http://www.i-mabbiopharma.com/
About I-Mab
I-Mab is a dynamic and fast-growing global player committed to developing innovative biologics in the areas of immuno-oncology and immuno-inflammation through internal R&D capabilities and global partnerships. I-Mab's pipeline is driven by the company's development strategy to address unmet needs in China and to bring innovative assets to the world.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Jingwu Zang
CSO: Taylor Guo
JOBS:
181 articles about I-Mab
-
I-Mab Announces Upcoming Participation at March Conferences
2/24/2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March.
-
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
2/10/2021
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for TJ210/MOR210 to initiate a phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics
-
Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
2/9/2021
A registered follow-on public offering by certain pre-IPO shareholders of 3,283,950 American depositary shares of I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, has priced on February 8, 2021 at a public offering price of US$54.0 per ADS.
-
Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
2/5/2021
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced the commencement of a proposed registered underwritten public offering by certain pre-IPO shareholders of American depositary shares, each ten ADSs representing twenty-three ordinary shares of the Company.
-
I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
2/4/2021
I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2 clinical trial ( NCT04600817 ) of TJ107 (efineptakin alpha), a novel long-acting reco
-
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
1/25/2021
I-Mab (Nasdaq: IMAB), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumors in the United States.
-
I-Mab Announces Upcoming Participation at January Conferences
12/23/2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in January. Details of the conferences and management presentation are as follows:
-
I-Mab Added to Nasdaq Biotechnology Index
12/14/2020
- Global biotech index widely followed and tracked by investors and ETFs - IMAB added to the index upon first annual review since IPO - To be effective prior to the U.S. market open on Monday, December 21, 2020 [14-December-2020] SHANGHAI and GAITHERSBURG, Md. , Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical st
-
I-Mab Files Shelf Registration Statement for PIPE Investors
12/1/2020
I-Mab filed a registration statement on Form F-1 with the Securities and Exchange Commission by using a "shelf" registration process with respect to 25,123,751 ordinary shares of the Company beneficially owned by certain shareholders, which are parties to the privately negotiated subscription agreements with the Company dated September 3, 2020.
-
I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
12/1/2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the strengthening of its Scientific Advisory Board ("SAB") with the appointment of leading international experts Dr. Chen Dong and Dr.
-
I-Mab to Hold Investor Call and Expand Clinical Data Analysis on Efficacy Signal of Lemzoparlimab from Phase 1 Clinical Trial
11/13/2020
I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that it will hold a call with investors on Friday, November 13 at 8:20 a.m. ET to provide deep dive analysis of preliminary clinical efficacy results of its U.S.
-
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting
11/9/2020
- Initial monotherapy results demonstrate differentiated safety and PK profile and efficacy signal of lemzoparlimab for the treatment of relapsed/refractory malignancy - I-Mab to host call for investors on November 9 at 8:30am ET
-
I-Mab Announces Upcoming Participation at November Conferences
10/28/2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follow
-
I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/27/2020
- Oral presentation will highlight the potent anti-tumor effects demonstrated by TJ210, a novel antibody that blocks C5aR by binding to a unique epitope
-
I-Mab to Present Phase 1 Data of Lemzoparlimab at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/15/2020
- Poster presentation highlights data from the U.S. phase 1 trial of lemzoparlimab, a highly differentiated anti-CD47 monoclonal antibody, for treatment of relapsed or refractory malignancy
-
I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency
9/30/2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today
-
I-Mab Announces Upcoming Participation at September Conferences
9/8/2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in September. Details of the conferences and management presentations are as follows:
-
I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium
9/4/2020
Ordinary Share Purchase price equivalent to $33.00 per ADS, at a premium to the 30-day volume weighted average price Demonstrates leading biotech investors' strong endorsement of I-Mab's R&D innovation and value generation capabilities
-
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
9/4/2020
AbbVie and I-Mab to collaborate on development and commercialization of I-Mab's highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
-
AbbVie and I-Mab announced today that they had entered a global collaboration agreement to develop and commercialize lemzoparlimab (also known as TJC4). The anti-CD47 monoclonal antibody was initially discovered and developed by I-Mab for the treatment of various cancers.